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2 SHAWE ET AL.followed. All available evidence was graded and further discussed during group meet-
ings to formulate recommendations. Where evidence of sufficient quality was lacking,
the group made consensus recommendations based on expert clinical experience. The
main outcome measures are timing of pregnancy, contraceptive choice, nutritional
advice and supplementation, clinical follow‐up of pregnancy, and breastfeeding. We
provide recommendations for periconception, antenatal, and postnatal care for
women following surgery. These recommendations are summarized in a table and
print‐friendly format. Women of reproductive age with a history of bariatric surgery
should receive specialized care regarding their reproductive health. Many recommen-
dations are not supported by high‐quality evidence and warrant further research.
These areas are highlighted in the paper.
KEYWORDS
bariatric surgery, metabolic surgery, obesity, pregnancy, obstetrics, gynaecology1 | INTRODUCTION
The prevalence of obesity worldwide has nearly tripled between 1975
and 2016. In 2016, 1.9 billion adults aged 18 years or older (40% of
women and 39% of men) were affected by overweight (BMI 25‐29
kg/m2) with 650 million (11% men and 15% women) having obesity
(BMI ≥ 30 kg/m2).1 Obesity increases complications for both mother
and offspring during pregnancy and childbirth.2 Furthermore, there is
growing evidence that parental nutrition and lifestyle affect embryonic
development with potential long‐term health implications for the infant
through on the process of developmental programming.3,4 As such, it is
generally recommended that both women and men with obesity lose
weight before conception.5,6 Based on international guidelines,7
patients with class III obesity (BMI ≥ 40 kg/m2) or class II obesity
(BMI 35‐39 kg/m2) with associated comorbidities may be eligible for
bariatric surgery (BS). Poor success with weight loss by diet alone has
led to BS becoming increasingly popular.8 Common procedures include
(1) sleeve gastrectomy (SG), the most frequently performed operation,9
in which the greater curvature of the stomach is resected, reducing
stomach volume by 75%, thus limiting food intake. This procedure also
removes ghrelin‐producing secreting endocrine cells present in the
greater curvature of the stomach, which aid in appetite reduction.
Weight loss as well as alterations in other metabolic hormones results
in the improvement of glucose homeostasis and results in positive
effects on comorbidities therefore reducing appetite and aiding in sub-
sequent diabetes remission.10 (2) Roux‐en‐Y gastric bypass (RYGB), a
mixed procedure in which the volume of the stomach is reduced to
approximately 15 to 30 mL and the absorption of nutrients, is impaired
by bypassing part of the small intestine and diverting the food flow to
the distant small intestine. This approach not only results in a limited
oral intake but also induces malabsorption, although this is reduced over
time because of intestinal hypertrophy. Furthermore, an increase in gut
hormone secretion (including GLP‐1 and PYY) hormones associated
with RYGB may diminish appetite and result in better glucosehomeostasis.11 (3) Adjustable gastric band (AGB) procedures where an
inflatable restrictive band is placed around the upper portion of the
stomach creating a small pouch with a narrow opening to the lower
stomach, adjusted by adding or removing fluid to the band via a subder-
mal port. This reduces stomach capacity and appetite.12 Other types of
surgery include biliopancreatic diversion with duodenal switch,
intragastric balloon, and vertical banded gastroplasty, but these are out-
dated or rarely performed.
As a result of weight loss and enteroendocrine alteration, BS has
also been shown to reduce the incidence of obesity‐related comorbid-
ities and complications.13 BS is however associated with a potential
increase in adverse events due to surgical complications and micronu-
trient deficiencies and derangements in (neuro)endocrine and meta-
bolic homeostasis.14-17 Approximately 80% of BS is in women, many
of whom are of reproductive age.18-20 BS may improve fertility
through restoration of ovulation, and pregnancies after BS are becom-
ing increasingly common.21 It has been recognized that changes in gut
anatomy and physiology with potential for malnutrition incur
increased potential for adverse perinatal outcomes such as small for
gestational age (SGA), preterm birth, congenital abnormalities, and
perinatal mortality. Pregnancy soon after surgery may increase risk
of maternal morbidity and/or mortality.22
A need for more specific guidance and nutritional management
was recognized, and an international group of experts was assembled
to review the available evidence and provide recommendations on the
periconception, antenatal, and postnatal care of pregnancies after BS.2 | METHODS
An expert meeting focused on pregnancy after BS was organized at
the University of Surrey, UK in April 2017 with a follow‐up meeting
at University Hospital Leuven, Belgium, in November 2017. These
meetings brought together national and international expertise from
TABLE 2 Type and level of evidence24
Quality and Level of Evidence
1++ High‐quality meta‐analyses, systematic reviews of RCTs, or RCTs
(including cluster RCTs) with a very low risk of bias
1+ Well‐conducted meta‐analyses, systematic reviews of RCTs, or
RCTs (including cluster RCTs) with a low risk of bias
1– Meta‐analyses, systematic reviews of RCTs, or RCTs (including
cluster RCTs) with a high risk of bias
2++ High‐quality systematic reviews of these types of studies, or
individual, non‐RCTs, case‐control studies, cohort studies, CBA
studies, ITS, and correlation studies with a very low risk of
confounding, bias or chance, and a high probability that the
relationship is causal
2+ Well‐conducted non‐RCTs, case‐control studies, cohort studies,
CBA studies, ITS, and correlation studies with a low risk of
confounding, bias or chance and a moderate probability that the
relationship is causal
2– Non‐RCTs, case‐control studies, cohort studies, CBA studies, ITS
and correlation studies with a high risk—or chance—of
confounding bias, and a significant risk that the relationship is
not causal
3 Non‐analytic studies (for example, case reports, case series)
4 Expert opinion, formal consensus
SHAWE ET AL. 3a multidisciplinary group of researchers and clinicians including spe-
cialists in obstetrics and gynaecology, bariatric surgery, endocrinology,
dietetics, nutrition, nursing and midwifery, health psychology, epide-
miology, and public health. Additional international colleagues were
able to join both meetings through teleconferencing.
The objectives of the meetings were to discuss the key questions,
to advance scientific knowledge and practice in the area of pregnancy
after BS, and to identify key areas of focus for collaborative work to
produce consensus clinical guidelines on best practice for facilitating
healthy pregnancies after BS.
The clinical guideline was developed using the structure from
ADAPTE.23 The group formulated specific clinical questions in relation
to pregnancy after BS (Table 1). For each question, a systematic search
of the available literature was performed, identifying articles published
from inception to July 2018. Search terms related to pregnancy (“preg-
nancy,” “prepregnancy,” “mother,” “maternal,” “conception,” “precon-
ception,” “gravid,” “pregravid”) were combined with terms related to
BS (“bariatric surgery,” “weight loss surgery,” “gastric bypass,” “Roux‐
en‐Y,” “RYGB,” “sleeve gastrectomy,” “gastric sleeve,” “gastroplasty,”
“gastric band,” “LAGB,” “biliopancreatic diversion,” “BPD,” “duodenal
switch”) and terms specific for each clinical question. Articles resulting
from these searches and relevant references cited in those articles
were reviewed. All evidence was graded (Table 2)24 and discussed dur-
ing group meetings. When evidence of sufficient quality was lacking,
the group made consensus recommendations based on expert clinical
experience. Consensus on the guidelines was declared when 100% of
the group agreed with the recommendations. The final document was
reviewed by all authors. The recommendations made by this group are
summarized in Table 3.3 | EVIDENCE AND RECOMMENDATIONS
3.1 | Bariatric surgery to conception interval
The period after BS is characterized by weight loss which may be rapid
after SG and RYGB procedures and slower after AGB, once optimalTABLE 1 Clinical questions to be answered in this guideline
Clinical Questions to be Answered in This Guideline
What is the recommended time interval between bariatric surgery and
conception?
What types of contraception should be advised to women after bariatric
surgery?
Are there special recommendations regarding dietary behaviour?
Which micronutrients should be monitored? Which types of
supplements should be prescribed?
Should patients be screened for gestational diabetes and how should
they be screened?
Which medical and surgical complications should be monitored, and can
they be prevented?
Is breastmilk composition affected by bariatric surgery and can it safely
be recommended to patients?adjustment has been achieved. During this period postsurgery,25,26
women are recommended to postpone pregnancy in order to ensure
maximal weight loss, weight stabilization, and to reduce the risk of
macronutrient and micronutrient deficiencies and electrolyte imbal-
ances.5 Evidence in regard to this recommendation is however scarce.
We identified 14 studies reporting on the surgery‐to‐conception inter-
val and pregnancy outcomes, but many studies have limitations in
methodology thus preventing comparison.
Parent et al22 found that a shorter surgery‐to‐birth interval (less
than 2 years) was associated with a higher risk for prematurity, SGA,
and neonatal intensive care unit (NICU) admission (level 2++), but data
on long‐term outcomes were missing. In contrast, Stentebjerg et al27
and Nomura et al28 found an increased risk for certain pregnancy com-
plications (iron deficiency, excessive gestational weight gain (GWG),
and delivery by caesarean section) if the pregnancy was postponed
according to this recommendation (level 2+). Norgaard et al29 found
no difference in the prevalence of SGA prior to, or after, 18 months
(level 2++). Other studies also did not find a difference in gestational
outcomes according to surgery to conception interval.27,30-37
Based on level 2++ evidence, the members of this group recom-
mend postponing pregnancy until a stable weight is achieved. This is
typically achieved 1 year after SG or RYGB procedures and 2 years
after AGB.
3.2 | Contraception
Women recommended to postpone pregnancy during the period of
rapid weight loss (1‐2 years) require adequate counselling regarding
safe and effective contraception.38 As obesity is associated with
impaired fertility due to metabolic syndrome and PCOS, patients
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SHAWE ET AL. 7may not be using contraception presurgery. They should be made
aware that fertility increases postoperatively, and contraception usage
should be discussed (level 2+).39 There is sufficient evidence to show
that perioperative contraceptive counselling increases the postopera-
tive use of contraception (level 2+).40,41 Contraceptive counselling
and contraceptive knowledge by health care providers could however
be improved (level 2−),42,43 as contraceptive use after BS is often sub-
optimal, with many women using least reliable methods (level
2+).39,40,44-48 This is even more important in patients with a history
of infertility, as they have been found to be at increased risk for
unprotected intercourse without intent to conceive and have higher
early postoperative conception rates.39
Both RYGB and, to a lesser extent, SG significantly alter the anatom-
ical structure of the gastrointestinal tract, and theoretically, this gut
shortening could affect the absorption of oral contraceptives containing
an oestrogen component which undergoes metabolism in the upper gut
wall. Absorption of ethinylestradiol from the contraceptive pill may be
reduced leading to a decrease in efficacy.49 Reliability might also
decrease due to postoperative side effects and complications such as
vomiting and/or diarrhoea; however, there are few data in women after
BS. Limited clinical evidence suggests no substantial decrease in effec-
tiveness of oral contraception among women who underwent a
biliopancreatic diversion (BPD), a now uncommon procedure, or
AGB.50,51 However, evidence from pharmacokinetic studies has shown
increased contraceptive failure for progestogen oral contraception
among women who underwent a jejunoileal bypass (an older proce-
dure).52,53 In general, combined oral contraception (COC) may be less
reliable after BS (level 2+).51 Additionally, many individuals are still
affected by obesity after BS, and this represents a relative contraindica-
tion for the use of COC, with both factors increasing the risk of venous
thromboembolism.38 Alternatives found to be unaffected by BS are par-
enteral long‐acting reversible contraception (LARC) methods such as the
copper intrauterine device (IUD), intrauterine systems (IUS), and proges-
togen implants. They have been found to be highly effective and accept-
able to women (level 2−).54-57 For women choosing nonhormonal barrier
methods, both male and female condoms may be suitable; however, the
contraceptive diaphragm may be difficult to insert correctly and less reli-
able as it requires refitting after every 3 kg of weight change.58
Consensus from available evidence is that women should receive
counselling regarding contraception prior to surgery (level 2−). Com-
bined oral contraception containing oestrogen should be avoided after
BS (level 2+). The use of long‐acting reversible contraception such as
implants, IUD, or IUS should be encouraged and offered as first line
following BS (level 2−).4 | NUTRITION AND MICRONUTRIENT
MONITORING
4.1 | Nutritional advice
A large proportion of pregnant women have a poor diet,59 indepen-
dent of BS history. The focus should remain on the regularmonitoring of diet quality and nutritional status and on encouraging
a general healthy dietary pattern and lifestyle.3 At the same time, a
healthy diet post‐BS may differ in food group proportions from that
of the nonsurgical pregnant population. This is due to a greater
emphasis on lean protein sources, followed by fruit and vegetables,
and lastly starchy carbohydrates, as the main component of the post
BS diet. There is little or no evidence‐based specific dietary (food‐
based) advice for pregnancies post BS and few published reports
of the dietary intakes of this population.60 It therefore seems pru-
dent to combine what we know about an appropriate postsurgical
diet with the accepted general dietary advice for pregnancy to pro-
vide appropriate guidance.
Energy requirements should be individualized on the basis of
prepregnancy BMI, GWG, and physical activity level, with limitations
on energy‐dense foods if excessive GWG is identified (level 2+).60
Beard et al61 recommend a minimum of 60 g of protein/day during
pregnancy post‐BS (level 4). However, subsequent antenatal achieve-
ment of protein requirements is more difficult following bypass oper-
ations.62 In the nonpregnant postsurgical patient, intakes of up to 1.5
g/kg ideal body weight/day are proposed (up to a maximum of 2.1 g/
kg).63 How this translates into pregnancy and in particular how ideal
body weight should be defined have not been studied.
Exposure to abnormal glucose levels during pregnancy, similar to
that seen in nonsurgical women with GDM, warrants dietary interven-
tion. In the case of hyperglycaemia, it is recommended to reduce rap-
idly absorbed carbohydrates, substituting them with protein and low
glycaemic index (GI) alternatives (level 4).
Parenteral nutrition support may be indicated in cases of severe
malnutrition during pregnancy64 with initiation and choice of feeding
route informed by local nutrition support protocols (level 4). In the
absence of dietary advice specific to the postsurgery population,
women should be encouraged to adhere to national guidelines regard-
ing diet, taking into consideration changes of anatomy due to BS.4.2 | Postprandial syndromes (dumping syndromes)
Postprandial syndrome, or dumping syndrome, is a common effect of
bariatric and metabolic surgery. Postprandial syndrome (also termed
early dumping syndrome) occurs within 60 minutes of ingestion of
food, typically rapidly absorbed carbohydrates, producing symptoms
including dizziness, flushing, and palpitations. If early dumping is
suspected, rapidly absorbed carbohydrates should be avoided. Addi-
tionally, liquids should not be taken 30 minutes before and after eating
to encourage a slower gastric transit (level 2−).65,66 Caffeinated bever-
ages should be avoided, and patients should be advised to eat slowly
and chew well. Individualized advice relating to portion sizes and
meal/snack frequency and spacing may be helpful alongside education
about the GI of different foods (level 4).66 Alcohol consumption can
precipitate dumping and is in general contraindicated throughout
pregnancy.67
Late dumping or postprandial hyperinsulinaemic hypoglycaemia
(PHH) is far less common, although the exact prevalence remains
8 SHAWE ET AL.unclear due to the lack of clear diagnostic criteria.68-70 PHH character-
ized by symptomatic hypoglycaemia that occurs after 60 minutes of
eating (typically between 60 and 180 minutes postprandial).71 This
syndrome should be considered in those who have symptoms of
hypoglycaemia (eg, altered mental state, anxiety, sweating, or altered
sensorium) that occur in parallel with biochemical evidence of
hypoglycaemia, and which then resolve on ingestion of carbohydrate
(ie, symptoms agree with Whipple's triad).71
In general, management of late dumping/PHH requires more care-
ful dietary manipulation (ie, low GI carbohydrates, small carbohydrate
portions, carbohydrates mixed with protein, frequent intake of six
small meals) and sometimes referral to an endocrinologist for further
investigation and medical management (level 4).72 There is no specific
approach for PPH described in pregnancy, although important
glycaemic excursions potentially could affect fetal growth and well‐
being.TABLE 4 Daily dose recommendations for (pre)pregnancy
supplementation
Daily Dose Recommendations for (Pre)pregnancy Supplementation
(Level 4)
Thiamine >12 mg
Folic acid 0.4 mg daily, during preconception and first trimester, 4‐5 mg
if obese or diabetic
Calcium 1200‐1500 mg in divided doses (includes dietary intake)
Vitamin D >40 mcg (1000 IU)
Iron 45‐60 mg elemental iron (AGB >18 mg)
Copper 2 mg (AGB >1 mg)
Zinc 8‐15 mg per 1 mg copper
Vitamin K 90‐120 μg
Vitamin E 15 mg
Vitamin A 5000 IU, should be in B carotene form in pregnancy
Selenium 50 μg daily
Abbreviations: IU, international units; AGB, adjustable gastric banding.4.3 | Nutritional supplementation and monitoring
Men and women after BS have an increased risk to develop micronu-
trient deficiencies.73 In the formulation of this guidance, it is recog-
nized that there is a lack of evidence on the optimal nutritional
monitoring and supplementation strategies in pregnancy after BS.
We have therefore used data and guidelines for the nonpregnant
postoperative population and supplemented this with pregnancy‐spe-
cific data when available. It should be noted that we recommend that
pregnancy should be planned and that nutritional supplementation
should be optimized preferably 3 to 6 months prior to conception
(level 4). A multivitamin and mineral supplement should be taken daily
prior to conception and throughout pregnancy (level 4). This supple-
ment should contain the following at a minimum: copper (2 mg), zinc
(15 mg), selenium (50 μg), folic acid (5 mg), iron (45‐60 mg or >18
mg after AGB), thiamine (>12 mg), vitamin E (15 mg), and beta‐caro-
tene (vitamin A, 5000 IU) (level 4). The retinol form of vitamin A
should be avoided during pregnancy due to teratogenicity risk (level
2+),74,75 and supplementation should be adjusted to maintain concen-
trations within normal limits (level 2−).76
Given the risk associated with potential deficiencies in the
periconception period, the following indices should be checked at
least every 3 months in women planning to become pregnant after
BS: serum folate or red blood cell folate (level 2−),77 serum vitamin
B12 or transcobalamin (level 2−),62,63,73,78,79 serum ferritin, iron stud-
ies (including transferrin saturation), full blood count (level
2−),63,73,76,78,79 and serum vitamin A levels (level 2−).76,80,81 In addi-
tion, the following should be monitored every 6 months: prothrombin
time, international normalized ratio (INR) (level 2+),82,83 serum 25‐
hydroxyvitamin D with calcium, phosphate, magnesium, and parathy-
roid hormone (PTH) (level 4), serum protein and albumin (level
2−),62,78 renal function and liver function tests (level 4), serum vitamin
E (level 4), serum zinc, copper, and selenium (level 4). Serum vitamin
K1 concentration should be monitored if coagulation studies are
abnormal (level 2+).83Specific supplementation is recommended in the preconception
and periconception period (Tables 3 and 4). In most patients after
BS, 0.4 mg per day of folic acid is sufficient as doses >0.3 mg are
not absorbed, due to lack of dihydrofolate reductase in intestinal cells.
Despite having undergone BS, many patients still have a BMI > 30 kg/
m2. Current guidelines suggest that additional folic acid at a dose of 4
or 5 mg daily should be given to these patients during the
periconception period and throughout the first trimester (level 4).84
Postsurgery vitamin B12 regimens should be continued preconception
at a dose of 1 mg every 3 months via intramuscular depot injection.
Alternatively, oral supplementation (1 mg/day) can be used to increase
compliance in the patient. However, a reduced absorption is to be
expected as the secretion of intrinsic factor is diminished (level 4).85
Additional vitamin B12 supplementation should be given as needed
to maintain serum concentrations within normal limits (level 4). Iron
supplementation should be continued at a minimum dose of 45 mg
of elemental iron daily (>18 mg for AGB); this should be increased as
needed to maintain ferritin within normal limits (level 4). Vitamin D
should be supplemented to maintain a concentration of 50 nmol/L
or greater with a serum PTH within normal limits (level 4). Calcium
should be added to on‐going vitamin D supplementation as needed
to maintain PTH within normal limits (level 4). If vitamin K1 deficiency
is measured or suggested by coagulation defects, it is advised to sup-
plement this with an oral dose of 10 mg weekly (level 2+).83
During pregnancy, serum levels of many micronutrients and mac-
ronutrients will decrease as a result of the expanding maternal blood
volume and increasing demands of the growing fetus. Therefore, it is
recommended to check the following indices at least once per trimes-
ter and use pregnancy‐specific ranges: serum folate (level 2−)77; serum
vitamin B12 (level 2−)62,63,73,78,79; serum ferritin, iron studies including
transferrin saturation and full blood count (level 2−)63,73,76,78,79; serum
vitamin D with calcium, phosphate, magnesium, and PTH (level 4);
serum vitamin A (level 2−)76,80,81; prothrombin time, INR, and serum
SHAWE ET AL. 9vitamin K1 concentration (level 2+)82,83; serum protein and albumin
(level 2−)62,78; and renal function and liver function tests (level 4). In
addition, we advise to monitor serum vitamin E, serum zinc, copper,
and selenium (level 4) during the first trimester.
During pregnancy, thiamine 300 mg daily with vitamin B complex
should be prescribed if prolonged vomiting occurs due to hyperemesis
or other causes (level 3).86-88
Furthermore, intravenous thiamine should be given at a minimum
dose of 100 mg daily with intravenous vitamin B complex if oral sup-
plementation is not possible due to the severity of vomiting (level
3).86-88 Further supplementation in regards to vitamin B12, iron, vita-
min D, calcium, vitamin A, and vitamin K should be provided as in the
preconception period (level 4).
Our recommendations for preconception nutritional supplementa-
tion generally agree with the British Obesity and Metabolic Surgery
Society (BOMSS) and the American Society of Metabolic and Bariatric
Surgeons (ASMBS) recommendations63,84 and represent the com-
monly agreed standard of care with regards to micronutrient
replacement.4.4 | Breastfeeding
Limited data are available on breastfeeding after BS. In longitudinal
studies, the composition of breastmilk from women after BS was
found to be largely comparable with women without prior BS (level
2++).89,90 Gimenes et al91 found children born to mothers who had
undergone BS and who were breastfed for at least 6 months to have
lower fat mass and lower glucose levels, possibly protecting them from
the development of obesity later in life. These authors therefore rec-
ommend breastfeeding in these women for at least 6 months in accor-
dance to the general WHO guidelines (level 2+).92 Case reports have
demonstrated adverse maternal and/or neonatal outcomes due to
micronutrient deficiencies during lactation (level 3).93-95 Therefore,
we advise supporting women wishing to breastfeed after BS (level
2+) and suggest that their nutritional status is closely monitored during
lactation with additional supplements to those routinely advised after
BS prescribed when necessary (level 3).5 | ASSESSMENT AND PREVENTION OF
MEDICAL COMPLICATIONS
5.1 | Ultrasound monitoring of fetal growth and
anomalies
Most types of BS have been found to double the risk of fetal growth
restriction (FGR) and SGA infants in comparison with BMI‐matched
women96 and women with obesity.97 This risk is higher with proce-
dures that potentially further induce malabsorption (such as RYGB),
when compared with procedures such as AGB or SG (level 2+).96,98
Studies suggest that it would seem preferable for women of reproduc-
tive age to consider more restrictive procedures to limit this risk. AGB
is however also associated with lower birth weight when the bandremains inflated during pregnancy (level 2++).99 Ultrasound monitor-
ing of fetal growth should be offered to all women with a history of
BS (level 2++). We recommend monthly screening from viability, espe-
cially in the presence of additional risk factors (eg, smokers, low GWG,
teenagers) (level 4).
It is still unclear whether BS increases the risk for congenital
malformations in the offspring as strong epidemiological data are lack-
ing.33 Several case reports and case studies have reported on the asso-
ciation between nutritional deficiencies in the mother and congenital
anomalies in the offspring (level 3).83,100-104 We therefore suggest
an additional detailed anomaly scan during the late first or second tri-
mester, especially in women with nutritional deficiencies (level 3), and
sonographic follow‐up of fetal growth during the third trimester (level
2++).5.2 | Weight management in pregnancy
Weight regain following BS is a known problem in a substantial num-
ber of patients.105-107 It is therefore important to avoid excessive
GWG and postpartum weight retention in women after BS. On the
other hand, insufficient GWG increases the risk for FGR and low birth
weight.108 So far, no specific guidelines for GWG during pregnancy in
postbariatric women are available and few studies have focussed on
the subject.
Overall, women with a history of BS gain less weight during preg-
nancy compared with women without prior BS, especially during the
third trimester (level 2++).27,109-113 Women who conceive within 18
months after surgery also appear to have less GWG in comparison
with those who conceive after this period (level 2+).27 Sheiner et
al114 compared GWG between different types of surgery and found
a reduced GWG for vertical banded gastroplasty and silastic ring ver-
tical gastroplasty when compared with RYGB, and higher GWG for
AGB compared with all other forms of BS (level 2+).
Studies correlating GWG and pregnancy outcome are scarce.
Ducarme et al111 reported a significant reduction in both low birth
weight (<10% centile) and macrosomia (>90% centile) after AGB
compared with controls with obesity, despite lower mean GWG. In
a small retrospective cohort, Santulli et al115 reported no clear rela-
tion between birth weight and GWG in women after RYGB (level
2−). Stentebjerg et al27 explored differences in outcome between
women who gained appropriate, inadequate, or excessive weight
according to the Institute of Medicine (IOM) guidelines for pregnant
women.116 GWG exceeding the guidelines increased the risk for pre-
eclampsia and low Apgar scores at 1 minute (level 2+). Women with
GWG below the guidelines delivered the smallest children. Lapolla et
al112 found a similar trend towards smaller children if GWG was
below the guidelines. As pregnancy does not appear to affect long‐
term weight in women with a history of BS (level 2+)25,26 and in
view of the strong correlation between insufficient GWG, adverse
neonatal outcomes, and increased risk of low birth weight in the
general population, we advise women with a history of BS to adhere
to the IOM guidelines (level 2+).
10 SHAWE ET AL.In women with AGB, evidence regarding band management and
weight gain during pregnancy is also limited. Active band management
appears to facilitate adherence to the IOM guidelines and was not
associated with low birth weight (level 2++).26,99,109,117 In contrast,
band deflation was associated with macrosomia (level 3).117
We recommend health professionals caring for women after BS to
measure BMI and monitor GWG in order to advise regarding adequate
GWG relating to their prepregnancy BMI in accordance to the IOM
guidelines (level 2+). If GWG is excessive, women should be assessed
for complications (level 2+). In the case of insufficient GWG, diet
should be revised and fetal growth carefully monitored (level 4).5.3 | Diabetes screening
Currently, there are no specific guidelines on screening and treatment
for diabetes during pregnancy in women after BS. The risk of develop-
ing type 2 diabetes (T2DM) and GDM is reduced in women after BS
when compared with women without BS matched for their preopera-
tive BMI.118 In contrast, women who have undergone BS are often
still affected by obesity or overweight and remain at higher risk for
T2DM and GDM than women with a healthy weight without
BS.96,119 Undiagnosed diabetes in pregnancy results in an increased
risk for adverse outcomes including fetal anomalies.120
Women who are planning to become pregnant post‐BS should be
screened for preexisting diabetes in the prepregnancy period, so that
it can be identified and treated prior to conception (level 4). During
pregnancy, women with a history of BS should routinely be screened
for GDM (level 4).121,122 Patients with other risk factors for develop-
ing GDM should be offered early screening according to local policies
to exclude preexisting diabetes. This is best performed using fasting
plasma glucose (FPG) or Hba1c (level 4). As data on cut‐off values dur-
ing pregnancies after bariatric surgery are lacking, we recommended
using the guideline from the American Diabetes Association
(ADA).123 As such, the diagnosis of T2DM is made if HbA1c and/or
FPG is greater than or equal to 6.5% and greater than or equal to
7.0 mmol/L, respectively. Care should be taken when using HbA1c
as it is less sensitive to screen for T2DM and GDM using this method
when compared with FPG. In addition, the HAPO study showed that
associations with adverse outcomes were significantly stronger with
glucose measures than with Hba1c.124 However, this is offset by the
test's greater practicality as it can be used in the nonfasting state,
and the wider application of a more convenient test may increase
the number of diagnoses made.
Oral glucose tolerance testing (OGTT) is appropriate for women
with AGB and can be used to screen for GDM between 24 and 28
weeks (level 4).122 However, given the physiological changes associ-
ated with RYGB, SG, and BPD, there are valid concerns with regards
to the tolerability (dumping) and accuracy of OGTT in these women
(level 2−).121,122,125 Studies have suggested that using either a
seven‐point capillary blood glucose (CBG) profile or continuous glu-
cose monitoring (CGM) or for 1 week between 24 and 28 weeks is
the most appropriate method for GDM screening in these women(level 4). However, appropriate threshold values for random capillary
glucose thresholds need yet to be defined in the post‐BS population.
In the absence of specific outcome data for the post‐BS popula-
tion, it seems reasonable to aim for the same targets as used in the
general population with GDM according to NICE126 or according to
local policies, that is maintaining capillary blood glucose concentra-
tions below 5.3 mmol/L fasting, 7.8 mmol/L 1 hour after eating, and
6.4 mmol/L 2 hours after eating, if these goals can be achieved with-
out hypoglycaemia (level 4). In women with a history of T2DM that is
in remission postoperatively, additional value may be gained from
screening with fasting glucose or HbA1c at booking and in the second
trimester (level 4).121 Screening in the third trimester should also be
considered if there is a clinical suspicion of the interval development
of diabetes (such as accelerated fetal growth indices).
If the diagnosis of GDM is made, it should be treated according to
local policies (level 4). In general, this consists of lifestyle interventions
first. If glycaemic targets are not met after 1 to 2 weeks, pharmacolog-
ical treatment should be considered.1275.4 | Mental health
BS is associated with an increased risk for mental health problems and
substance abuse.128-130 Data on mental health and substance abuse
during pregnancies after BS are very limited. Higher anxiety rates dur-
ing pregnancy are reported, without significant increase in depression
rates (level 2+).131 We found no data on postpartum depression fol-
lowing BS. Guelinckx et al60 reported on maternal smoking during
the first trimester of pregnancy in post‐BS women. Overall smoking
rate was 24%, without a clear relation to the type of procedure.
Smoking prevalence was comparable with the general nonpregnant
female population, but much higher than in the general pregnant pop-
ulation in the same region (6%). No studies were found reporting on
alcohol or other substance abuse during pregnancies after BS. As such,
we recommend health providers to screen for anxiety and other men-
tal health disorders prior and during pregnancy, and follow‐up should
be offered when necessary (level 2+). Smoking cessation and alcohol
use should be discussed when necessary as per general prepregnancy
guidance (level 2−).5.5 | Assessment and prevention of surgical
complications
Evidence for two common surgical complications during pregnancy
was found: internal herniation following RYGB and gastric band slip-
page following AGB. With regards to internal herniation, an incidence
of 8% has been reported during pregnancies after RYGB.132 Upper
abdominal pain complicates 46% of such pregnancies, and internal
herniation is diagnosed in 32.8% of these cases (level 3).133 Women
reporting abdominal pain had an increased risk of preterm birth and
significantly lower birth weight compared with women without
abdominal pain, suggesting that severe abdominal pain and abdominal
surgery may induce uterine contractions (level 3).133 Repeat internal
SHAWE ET AL. 11herniation can occur in the same pregnancy even after previous clo-
sure of mesenteric defects (level 3). In a review of 22 cases of internal
herniation during pregnancy after BS, all patients presented with
abdominal pain and half of patients presented with nausea and/or
vomiting. The most common location of the hernia was Petersen's
space (45.5%), and there was a high incidence of maternal and fetal
death in this case series (9% and 13.6%, respectively) (level 2−).134 A
systematic review reported that all maternal and perinatal deaths in
pregnancies complicated by internal herniation after RYGB occurred
in women treated later than 48 hours after symptom onset (level 2+
+).135
We recommend that all women with RYGB should be advised
about the risks and symptoms of internal herniation and should seekFIGURE 1 Print‐friendly presentation of the recommendations for health
wileyonlinelibrary.com]appropriate medical assistance without delay. Care providers should
be advised that any pregnant women with a history of RYGB that pre-
sents with abdominal pain should be assumed to have a small bowel
obstruction due to internal herniation until proven otherwise (level
4)136 and that imaging techniques and operative intervention, often
performed with reluctance in pregnant women, should not be delayed
(level 2++).
Gastric band slippage may be increased during pregnancy due to
vomiting and increased intraabdominal pressure. One study reported
an incidence of 12% during pregnancy compared with 3% to 5% in
the general AGB population (level 3).137 A shorter time interval
between AGB and pregnancy was associated with a higher rate of pri-
mary band revisions after pregnancy (level 2+).138 Patients should bey pregnancies after bariatric surgery. [Colour figure can be viewed at
12 SHAWE ET AL.counselled on the risk and symptoms of band slip during pregnancy
and in the postpartum period (level 4).5.6 | Research gaps
The recommendations issued in this review are based on a systematic
research of the literature by a multidisciplinary group of international
experts. The group has identified areas for which the level of evidence
and therefore the quality of the recommendations is largely based on
expert opinion. It is felt by the group that following areas need further
robust investigation with regard to women and children's health in
pregnancy following BS:
• Contraceptive counselling, safety, efficacy, and use
• Timing of pregnancy
• Gestational weight gain recommendations
• Nutrition during pregnancy
• Optimal macronutrient monitoring and substitution/supplementa-
tion such as protein intake, including management of supplementa-
tion and when parental nutrition should be considered
• Optimal micronutrient monitoring and substitution
• Prevention and treatment of dumping and PPH
• Monitoring of fetal growth
• Screening and treatment for GDM
• Screening and treatment of surgical complications
• Mental health and substance abuse6 | CONCLUSIONS
This review summarizes current recommendations on the
periconception, antenatal, and postnatal care of women following
BS. Recommendations on the care of these patients are summarized
in Table 3 and presented in a print‐friendly format for practical use
in the clinical setting (Figure 1). Our work highlights the paucity of
studies on the optimal care for this growing group of women and iden-
tifies research gaps in this field. The publication of these guidelines
will be the first step in a research collaboration which will address
these unanswered questions.ACKNOWLEDGEMENTS
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